Lisata Therapeutics Stock Investor Sentiment

LSTA Stock  USD 3.73  0.02  0.54%   
About 50% of Lisata Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Lisata Therapeutics suggests that some traders are interested. The current market sentiment, together with Lisata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lisata Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
over three weeks ago at insidermonkey.com         
Why Pacific Biosciences of California Is the Worst ARK Stock to Buy According to Short Sellers
insidermonkey News
over three weeks ago at businesswire.com         
Fonseca Biosciences Secures Exclusive US Rights to XTORO 0.3 percent to Treat Swimmers Ear
businesswire News
over three weeks ago at finance.yahoo.com         
Fonseca Biosciences Secures Exclusive US Rights to XTORO 0.3 percent to Treat Swimmers Ear
Yahoo News
over three weeks ago at finance.yahoo.com         
Lisata Therapeutics Completes Enrollment for Cancer Therapy Trial
Yahoo News
over three weeks ago at thelincolnianonline.com         
Lisata Therapeutics Given Buy Rating at HC Wainwright
news
over three weeks ago at gurufocus.com         
Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial
Gurufocus Stories at Macroaxis
over three weeks ago at finance.yahoo.com         
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corpo...
Yahoo News
over three weeks ago at gurufocus.com         
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and ...
Gurufocus Stories at Macroaxis
over three weeks ago at gurufocus.com         
IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential ...
Gurufocus Stories at Macroaxis
over three weeks ago at investing.com         
Castle Biosciences CEO Derek Maetzold sells 160,741 in shares
Investing News at Macroaxis
over a month ago at simplywall.st         
Retail investors among Bright Minds Biosciences Inc.s largest stockholders and were hit after last w...
Simply Wall St News at Macroaxis
over a month ago at finance.yahoo.com         
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezucl...
Yahoo News
over a month ago at thelincolnianonline.com         
Amarillo Biosciences Signs Memorandum of Understanding for Collaboration with Taiwan Tanabe Seiyaku
news
over a month ago at thelincolnianonline.com         
Sagimet Biosciences Earns Outperform Rating from Analysts at Oppenheimer
news
over a month ago at prnewswire.com         
HAREHOLDER ALERT The MA Class Action Firm Investigates the Merger of Arcadia Biosciences, Inc. - RKD...
prnewswire News
Far too much social signal, news, headlines, and media speculation about Lisata Therapeutics that are available to investors today. That information is available publicly through Lisata media outlets and privately through word of mouth or via Lisata internal channels. However, regardless of the origin, that massive amount of Lisata data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Lisata Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Lisata Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Lisata Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Lisata Therapeutics alpha.

Lisata Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Lisata Stock analysis

When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity